NCT06090461View on ClinicalTrials.gov

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

CompletedOBSERVATIONAL
Enrollment

31,889

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Obesity
Trial Locations (1)

37027

Currax Pharmaceuticals, Brentwood

Sponsors
All Listed Sponsors
lead

Currax Pharmaceuticals

INDUSTRY

NCT06090461 - Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.) | Biotech Hunter | Biotech Hunter